Abivax plunges 32% as ulcerative colitis drug efficacy overshadowed by cancer concerns
Source: SeekingAlpha
2026-06-02 04:23:54 ET
In the study cohort, there was one reported case each of prostate cancer, breast cancer, and colonic dysplasia, which the company said were unrelated to treatment. There were also four cases of skin cancer on the higher 50 mg dose, of which two were deemed not or unlikely related to the drug, and the other two had a medical history of skin cancer, Abivax ( ABVX ) said ....
Read the full article on Seeking Alpha
For further details see:
Abivax plunges 32% as ulcerative colitis drug efficacy overshadowed by cancer concerns
Abivax SA
NASDAQ: ABVX
ABVX Trading
3.27% G/L:
$99.835 Last:
1,550,008 Volume:
$105.18 Open:
ABVX Latest News
June 03, 2026 08:53:00 pm
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
June 02, 2026 09:20:00 pm
Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)
ABVX Stock Data
$9,359,969,582
53,161,297
N/A
64
N/A
Biotechnology & Life Sciences
Healthcare
FR
Paris
